These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33462096)

  • 1. Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study.
    van der Veen L; Segers M; van Raay JJ; Gerritsma-Bleeker CL; Brouwer RW; Veeger NJ; van Hulst M
    BMJ Open; 2021 Jan; 11(1):e040336. PubMed ID: 33462096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA).
    Veen Lv; van Raay JJ; Gerritsma-Bleeker CL; Veeger NJ; Hulst Mv
    BMJ Open; 2013 Jan; 3(1):. PubMed ID: 23355673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of rivaroxaban for the prevention of thrombosis following total hip or knee replacement: A systematic review and meta-analysis.
    Liu J; Zhao J; Yan Y; Su J
    Medicine (Baltimore); 2019 Mar; 98(9):e14539. PubMed ID: 30817570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile.
    Highcock AJ; As-Sultany M; Finley R; Donnachie NJ
    J Arthroplasty; 2020 Nov; 35(11):3093-3098. PubMed ID: 32674939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
    Trkulja V; Kolundzic R
    Croat Med J; 2010 Apr; 51(2):113-23. PubMed ID: 20401953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study.
    Schelde AB; Petersen J; Jensen TB; Gromov K; Overgaard S; Olesen JB; Jimenez-Solem E
    Bone Joint J; 2021 Oct; 103-B(10):1571-1577. PubMed ID: 34587805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
    Ning GZ; Kan SL; Chen LX; Shangguan L; Feng SQ; Zhou Y
    Sci Rep; 2016 Mar; 6():23726. PubMed ID: 27020475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
    Anderson DR; Dunbar M; Murnaghan J; Kahn SR; Gross P; Forsythe M; Pelet S; Fisher W; Belzile E; Dolan S; Crowther M; Bohm E; MacDonald SJ; Gofton W; Kim P; Zukor D; Pleasance S; Andreou P; Doucette S; Theriault C; Abianui A; Carrier M; Kovacs MJ; Rodger MA; Coyle D; Wells PS; Vendittoli PA
    N Engl J Med; 2018 Feb; 378(8):699-707. PubMed ID: 29466159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
    Özler T; Uluçay Ç; Önal A; Altıntaş F
    Acta Orthop Traumatol Turc; 2015; 49(3):255-9. PubMed ID: 26200403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus nadroparin for thromboprophylaxis following thoracic surgery for lung cancer: A randomized, noninferiority trial.
    Zhao M; Bao Y; Jiang C; Chen L; Xu L; Liu X; Li J; Yang Y; Jiang G; Li J; She Y; Chen Q; Shen L; Chen C
    Am J Hematol; 2023 Aug; 98(8):1185-1195. PubMed ID: 37139837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
    Squizzato A; Lussana F; Cattaneo M
    Thromb Haemost; 2015 Aug; 114(2):237-44. PubMed ID: 25946985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
    Xie J; Ma J; Huang Q; Yue C; Pei F
    Med Sci Monit; 2017 Feb; 23():704-711. PubMed ID: 28174415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
    Ricket AL; Stewart DW; Wood RC; Cornett L; Odle B; Cluck D; Freshour J; El-Bazouni H
    Ann Pharmacother; 2016 Apr; 50(4):270-5. PubMed ID: 26783354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    Matharu GS; Kunutsor SK; Judge A; Blom AW; Whitehouse MR
    JAMA Intern Med; 2020 Mar; 180(3):376-384. PubMed ID: 32011647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study.
    Yhim HY; Lee J; Lee JY; Lee JO; Bang SM
    PLoS One; 2017; 12(5):e0178214. PubMed ID: 28542415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.